Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukemi, hårig cell - antineoplastiska medel - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemic - immunsuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonell sjukdom, kronisk obstruktiv - läkemedel mot obstruktiv lungsjukdom, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - läkemedel mot obstruktiv lungsjukdom, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immunförsvaret sera och immunglobuliner, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiska medel - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanediol monohydrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - läkemedel som används vid diabetes - qtern, fast dos kombination av saxagliptin och dapagliflozin, är indicerat hos vuxna i åldern 18 år och äldre med typ 2-diabetes mellitus:för att förbättra glykemisk kontroll när metformin och/eller sulphonylurea (su) och en av de monocomponents av qtern inte ger tillräcklig glykemisk kontroll,när du redan behandlas med gratis kombination av dapagliflozin och saxagliptin. (se avsnitt 4. 2, 4. 4, 4. 5 och 5. 1 om det finns tillgängliga uppgifter om kombinationer studerade.

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

astrazeneca ab - ampicillinnatrium - suppositorium - 125 mg - ampicillinnatrium 133 mg aktiv substans - ampicillin